TaiMed Biologics (ROCO:4147) ROE % Adjusted to Book Value: -1.63% (As of Dec. 2025)


ROCO:4147 TaiMed Biologics Inc ROCO:4147
55 GF Score
Price NT$69.50
GF Value NT$85.90
Valuation Modestly Undervalued
View Full Analysis

What is TaiMed Biologics ROE % Adjusted to Book Value?

TaiMed Biologics ROCO:4147 55 ROE % Adjusted to Book Value is -1.63% as of Dec. 2025. GuruFocus rates ROCO:4147 with a GF Score™ of 55/100 and a GF Value™ of NT$85.90 (Modestly Undervalued).

TaiMed Biologics's ROE % for the quarter that ended in Dec. 2025 was -7.05%. TaiMed Biologics's PB Ratio for the quarter that ended in Dec. 2025 was 4.33. TaiMed Biologics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was -1.63%.

TaiMed Biologics ROE % Adjusted to Book Value Related Terms

TaiMed Biologics ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for TaiMed Biologics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TaiMed Biologics ROE % Adjusted to Book Value Chart

TaiMed Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.45 -1.45 -0.91 -1.05 -0.98

TaiMed Biologics Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.02 -0.43 -0.95 -0.27 -1.63

ROCO:4147 vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, TaiMed Biologics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TaiMed Biologics ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TaiMed Biologics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where TaiMed Biologics's ROE % Adjusted to Book Value falls into.


ROCO:4147
55GF Score
TaiMed Biologics Inc ROCO:4147
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TaiMed Biologics ROE % Adjusted to Book Value Calculation

TaiMed Biologics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-4.26% / 4.33
=-0.98%

TaiMed Biologics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-7.05% / 4.33
=-1.63%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -1.63% mean?
TaiMed Biologics (ROCO:4147) has a ROE % Adjusted to Book Value of -1.63% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on TaiMed Biologics and its competitors.
Is TaiMed Biologics' ROE % Adjusted to Book Value too high?
TaiMed Biologics' current ROE % Adjusted to Book Value is -1.63%. Overall, TaiMed Biologics has a GF Score™ of 55/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TaiMed Biologics' ROE % Adjusted to Book Value compare to VRTX and REGN?
TaiMed Biologics' ROE % Adjusted to Book Value of -1.63% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on TaiMed Biologics and its competitors. TaiMed Biologics's current ROE % Adjusted to Book Value is -1.63%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TaiMed Biologics stock overvalued right now?
Based on GuruFocus' analysis, TaiMed Biologics (ROCO:4147) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$85.90, compared to a current price of NT$69.50 — trading 19.1% below its estimated fair value. The current ROE % Adjusted to Book Value is -1.63%. TaiMed Biologics' overall GF Score™ is 55/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For TaiMed Biologics (ROCO:4147), the current ROE % Adjusted to Book Value is -1.63% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TaiMed Biologics (ROCO:4147) Overvalued in 2026?

Based on GuruFocus' analysis, TaiMed Biologics stock appears to be undervalued. The current stock price of NT$69.50 is trading 19.1% below its estimated GF Value™ of NT$85.90. GuruFocus considers TaiMed Biologics to be Modestly Undervalued.

Key valuation signals for ROCO:4147:

  • ROE % Adjusted to Book Value: -1.63%
  • GF Value™: NT$85.90 vs. price of NT$69.50 (19.1% below fair value)
  • GF Score™: 55/100

No single metric tells the full story. See the ROCO:4147 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TaiMed Biologics Business Description

Address No. 607, Ruiguang Road, 3rd Floor, Neihu District, Taipei, TWN, 11492
TaiMed Biologics Inc is a biotechnology company engaged in developing, manufacturing, and commercializing new drugs for the treatment and prevention of infectious diseases. Its products include Trogarzo IV Infusion, Trogarzo IV Push, TMB-365, TMB-365/TMB-380 combination, and Antibody-Drug Conjugates (ADCs). The Group operates in the Americas, which generates maximum revenue, as well as Europe and Taiwan.
55GF Score

Get the complete analysis for ROCO:4147

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$69.50
Price
NT$85.90
GF Value